Agios Pharm
$ 30.39
0.63%
24 Feb - close price
- Market Cap 1,769,484,000 USD
- Current Price $ 30.39
- High / Low $ 31.02 / 29.71
- Stock P/E N/A
- Book Value 20.41
- EPS -7.12
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.20 %
- ROE -0.30 %
- 52 Week High 46.00
- 52 Week Low 22.24
About
Agios Pharmaceuticals, Inc., a biopharmaceutical company, is dedicated to drug discovery and development in the field of cellular metabolism and adjacent areas of biology. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$38.88
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-12 | 2025-10-30 | 2025-07-31 | 2025-05-01 | 2025-02-13 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-02-15 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -1.85 | -1.78 | -1.93 | -1.55 | -1.74 | -1.47 | -1.69 | -1.45 | -1.72 | -1.64 | -1.51 | -1.47 |
| Estimated EPS | -1.95 | -1.91 | -1.75 | -1.76 | -1.63 | 7.91 | -1.6 | -1.65 | -1.65 | -1.7 | -1.56 | -1.7 |
| Surprise | 0.1 | 0.13 | -0.18 | 0.21 | -0.11 | -9.38 | -0.09 | 0.2 | -0.07 | 0.06 | 0.05 | 0.23 |
| Surprise Percentage | 5.1282% | 6.8063% | -10.2857% | 11.9318% | -6.7485% | -118.5841% | -5.625% | 12.1212% | -4.2424% | 3.5294% | 3.2051% | 13.5294% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AGIO
2026-02-23 02:56:01
This article analyzes Agios Pharmaceuticals Inc. (NASDAQ: AGIO) using AI models to identify momentum shifts and provide trading strategies. It highlights a near-term strong sentiment with a neutral mid and long-term outlook, alongside an exceptional risk-reward short setup. The analysis offers specific entry, target, and stop-loss levels for position, momentum breakout, and risk hedging strategies across different time horizons.
2026-02-22 06:40:05
Agios Pharmaceuticals (AGIO) reported a Q4 loss, but managed to beat revenue estimates for the quarter. This indicates some positive financial performance despite overall losses.
2026-02-18 20:57:58
Rock Springs Capital Management LP sold 159,379 shares of Agios Pharmaceuticals (NASDAQ:AGIO) in Q4, an estimated $5.59 million transaction due to the stock's 50% crash in November after a clinical trial setback. The fund's stake in Agios now represents 1.12% of its AUM, a reduction from 2.2% in the prior quarter, as the stock has fallen 16% over the past year.
2026-02-18 09:27:43
Eagle Health Investments LP significantly reduced its stake in Agios Pharmaceuticals (NASDAQ: AGIO) by selling 84,600 shares, a 25.6% trim, now holding 246,230 shares valued at approximately $9.88 million. Despite this, several analysts have recently raised their price targets on AGIO, contributing to a "Hold" average rating with an average target price of $39.78. Meanwhile, company insiders have also sold a total of 33,303 shares in the last quarter, representing a 4.93% ownership in the company.
2026-02-17 21:27:43
Agios Pharmaceuticals saw its stock drop 16% over the past year, significantly underperforming the S&P 500, following a 50% crash in November due to a clinical trial setback. Rock Springs Capital Management consequently reduced its stake in Agios by 159,379 shares, totaling an estimated $5.59 million. This transaction decreased Agios's representation in the fund's assets under management from 2.2% to 1.12%.
2026-02-17 12:28:08
The global Alpha Thalassemia Market is projected to reach US$ 1.9 billion by 2031, growing from US$ 1.1 billion in 2022 at a CAGR of 7.4%. North America is expected to lead with a 35% market share, driven by advanced healthcare infrastructure and genetic testing. Key market drivers include the increasing prevalence of genetic blood disorders, diagnostic advancements, and growing awareness, with major companies like Agios Pharmaceuticals, Actis, and Novartis Pharmaceuticals Corporation shaping the market through therapeutic innovation and expanded access.
